Dronabinol Safe and Effective for Neuropathic Pain Associated With Multiple Sclerosis
Pain intensity was not significantly reduced by dronabinol, compared with placebo after 16 weeks of treatment.
Neuropathic-like knee pain may be driven by central risk factors that include depression, anxiety, and pain catastrophizing.
The treatment is currently being evaluated in a Phase 2 study (ELEVATE) in patients with major depressive disorder who have had an inadequate response to standard antidepressant therapy.
The efficacy of a diagnostic nerve block may be a poor predictor of the success of surgery for focal nerve injury.